Abstract
Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering alternative mechanisms of modulating IgE pathway.
The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory diseases.
Keywords: Allergic rhinitis, asthma, IgE, ligelizumab, MEDI4212, omalizumab, quilizumab, rhinosinusitis.
Graphical Abstract
Current Respiratory Medicine Reviews
Title:An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases
Volume: 13 Issue: 1
Author(s): Amelia Licari , Riccardo Castagnoli, Elisa Panfili, Alessia Marseglia, Ilaria Brambilla and Gian Luigi Marseglia*
Affiliation:
- Department of Pediatrics, University of Pavia, Pavia,Italy
Keywords: Allergic rhinitis, asthma, IgE, ligelizumab, MEDI4212, omalizumab, quilizumab, rhinosinusitis.
Abstract: Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering alternative mechanisms of modulating IgE pathway.
The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory diseases.
Export Options
About this article
Cite this article as:
Licari Amelia , Castagnoli Riccardo , Panfili Elisa , Marseglia Alessia , Brambilla Ilaria and Luigi Marseglia Gian *, An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases, Current Respiratory Medicine Reviews 2017; 13 (1) . https://dx.doi.org/10.2174/1573398X13666170616110738
DOI https://dx.doi.org/10.2174/1573398X13666170616110738 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome
Current Pharmaceutical Design Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Neutrophil Activation Induced by Plant Lectins: Modulation of Inflammatory Processes
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy Targeting Pattern Recognition Receptors (PRRs) in Nano- Adjuvants: Current Perspectives
Current Bionanotechnology (Discontinued) Regulation of Cytokine Production by γδ T Cells
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Potential for Genetically Altered Microglia to Influence Glioma Treatment
CNS & Neurological Disorders - Drug Targets Appreciating the Balance between Classical Interleukin (IL)-6 Receptor Signaling and IL-6 Trans-Signaling: Implications for Arthritis Progression
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design The Obesity Hypoventilation Syndrome
Current Respiratory Medicine Reviews Improving DNA Vaccine Performance Through Vector Design
Current Gene Therapy Revealing Changes in Curcumin Bioavailability using Vitamin C as an Enhancer by HPLC-MS/MS
Current Pharmaceutical Analysis Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry Development Steps of Pharmacokinetics: A Perspective on Bioanalytical Methods and Bioequivalence
Current Clinical Pharmacology Therapeutic Potential of Alkaloids as Anti-Bacterial Agents: Drugs of Future
Current Bioactive Compounds Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry Evaluation of Novel 7-(hetero)aryl-substituted Pyrazolo[1, 5-a]pyrimidines as Phosphodiesterase-4 Inhibitors
Letters in Drug Design & Discovery MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Antimicrobial Peptides in Burns and Wounds
Current Protein & Peptide Science